Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing - 2Lockheed Martin opens new hypersonic weapons facility
- 3A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- 4German finance minister sees advantages of smartphones in schools
- 5UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- 2024 Moving Styles for Kitchen Redesigns
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- 4 Famous Attractions at Disneyland
- Surprising links between autism, Alzheimer’s could change how we treat both
- SF Chinatown's historic Empress of China building being revived into cultural campus
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Grass Care Administrations for a Wonderful, Sound Yard
- Fundamental Home Machines for Improved Solace in Summer
